By Professor David Goldstein

Journal articles

Yang JL; Lim HJ; Wang X; Crowe PJ; Goldstein D, 2016, 'Targeting the PI3K/PTEN/AKT/mTOR Pathway in Treatment of Sarcoma Cell Lines', Anticancer research, 36, pp. 5765 - 5772, http://dx.doi.org/10.21873/anticanres.11160

Kandula T; Park SB; Cohn RJ; Krishnan AV; Farrar MA; Goldstein D, 2016, 'Pediatric chemotherapy induced peripheral neuropathy: A systematic review of current knowledge', Cancer Treatment Reviews, 50, pp. 118 - 128, http://dx.doi.org/10.1016/j.ctrv.2016.09.005

Vickers MM; Lee C; Tu D; Wheatley-Price P; Parulekar W; Brundage MD; Moore MJ; Au H; O'Callaghan CJ; Jonker DJ; Ringash J; Goldstein D, 2016, 'Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3', Pancreatology, 16, pp. 1106 - 1112, http://dx.doi.org/10.1016/j.pan.2016.08.013

Chiorean EG; Von Hoff DD; Tabernero J; El-Maraghi R; Ma WW; Reni M; Harris M; Whorf R; Liu H; Li JS; Manax V; Romano A; Lu B; Goldstein D, 2016, 'Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer (vol 115, pg 188, 2016)', BRITISH JOURNAL OF CANCER, 115, pp. E13 - U13, http://dx.doi.org/10.1038/bjc.2016.306

Huguet F; Goldstein D; Hammel P, 2016, 'Radiation therapy deviations in trial of locally advanced pancreatic cancer: In Reply', JAMA - Journal of the American Medical Association, 316, pp. 1409 - 1410, http://dx.doi.org/10.1001/jama.2016.9781

de Souza P; Chua W; Clarke S; Goldstein D; Lee C, 2016, 'Inflammatory Markers Have a Role in Renal Cell Carcinoma Prognosis', European Urology Focus, 2, pp. 341 - 342, http://dx.doi.org/10.1016/j.euf.2016.04.007

Gormly KL; Coscia C; Wells T; Tebbutt N; Harvey JA; Wilson K; Schmoll HJ; Price T; Hruby G; Jeffery M; Karapetis C; Ng W; Singhal N; Burge M; Lynch R; Briscoe K; Begbie S; Gill S; Sebesan S; Goldstein D; Ng S; Asghari R; Blum R; Walpole E; Byard I, 2016, 'MRI rectal cancer in Australia and New Zealand: An audit from the PETACC-6 trial', Journal of Medical Imaging and Radiation Oncology, 60, pp. 607 - 615, http://dx.doi.org/10.1111/1754-9485.12493

Wang X; Goldstein D; Crowe PJ; Yang JL, 2016, 'Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: A review of the evidence', OncoTargets and Therapy, 9, pp. 5461 - 5473, http://dx.doi.org/10.2147/OTT.S94745

Burmeister EA; Waterhouse M; Jordan SJ; O'Connell DL; Merrett ND; Goldstein D; Wyld D; Beesley V; Gooden H; Janda M; Neale RE, 2016, 'Determinants of survival and attempted resection in patients with non-metastatic pancreatic cancer: An Australian population-based study', Pancreatology, 16, pp. 873 - 881, http://dx.doi.org/10.1016/j.pan.2016.06.010

Pavlakis N; Sjoquist KM; Martin AJ; Tsobanis E; Yip S; Kang YK; Bang YJ; Alcindor T; O'Callaghan CJ; Burnell MJ; Tebbutt NC; Rha SY; Lee J; Cho JY; Lipton LR; Wong M; Strickland A; Kim JW; Zalcberg JR; Simes J; Goldstein D, 2016, 'Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): A multinational placebo-controlled phase II Trial', Journal of Clinical Oncology, 34, pp. 2728 - 2735, http://dx.doi.org/10.1200/JCO.2015.65.1901

Waterhouse MA; Burmeister EA; O’Connell DL; Ballard EL; Jordan SJ; Merrett ND; Goldstein D; Wyld D; Janda M; Beesley VL; Payne ME; Gooden HM; Neale RE, 2016, 'Determinants of Outcomes Following Resection for Pancreatic Cancer—a Population-Based Study', Journal of Gastrointestinal Surgery, 20, pp. 1471 - 1481, http://dx.doi.org/10.1007/s11605-016-3157-4

Beesley V; Wockner L; O'Rourke P; Janda M; Merrett H; Goldstein D; Gooden H; Merrett N; O'Connell D; Rowlands I; Wyld D; Neale R, 2016, 'Erratum to: Risk factors for current and future unmet supportive care needs of people with pancreatic cancer. A longitudinal study (Support Care Cancer, 10.1007/s00520-016-3212-4)', Supportive Care in Cancer, 24, pp. 3601 - 3602, http://dx.doi.org/10.1007/s00520-016-3251-x

Beesley VL; Wockner LF; O’Rourke P; Janda M; Goldstein D; Gooden H; Merrett ND; O’Connell DL; Rowlands IJ; Wyld DK; Neale RE, 2016, 'Risk factors for current and future unmet supportive care needs of people with pancreatic cancer. A longitudinal study', Supportive Care in Cancer, 24, pp. 3589 - 3599, http://dx.doi.org/10.1007/s00520-016-3212-4

Ferraro D; Goldstein D; O'Connell RL; Zalcberg JR; Sjoquist KM; Tebbutt NC; Grimison P; McLachlan S; Lipton LL; Vasey P; Gebski VJ; Aiken C; Cronk M; Ng S; Karapetis CS; Shannon J; Do V; Marschner I; Friedlander M; Gurney H; Simes J; Hague W; O’Connell R; Gorzeman M; Pike R; Miranda K; Waring P; Lau D; Fox S; Liu Y; Wood T; Cocks C; Simmons K; McCourt J; Jefford M; Hobinchet A; Mirco B; Sagong J; Dudukovic S; Aghmesheh M; Parker S; Segelov E; Ratnayake L; Ranieri N; Varma S; Page J; Heyer E; Abdi E; Chorlton C; Wilkinson L; Marshall I, 2016, 'TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer', Cancer Chemotherapy and Pharmacology, 78, pp. 361 - 367, http://dx.doi.org/10.1007/s00280-016-3089-4

Vernerey D; Huguet F; Vienot A; Goldstein D; Paget-Bailly S; Van Laethem JL; Glimelius B; Artru P; Moore MJ; André T; Mineur L; Chibaudel B; Benetkiewicz M; Louvet C; Hammel P; Bonnetain F, 2016, 'Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)', British Journal of Cancer, 115, pp. 281 - 289, http://dx.doi.org/10.1038/bjc.2016.212

Chiorean EG; Von Hoff DD; Tabernero J; El-Maraghi R; Ma WW; Reni M; Harris M; Whorf R; Liu H; Li JS; Manax V; Romano A; Lu B; Goldstein D, 2016, 'Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer', British Journal of Cancer, 115, pp. 188 - 194, http://dx.doi.org/10.1038/bjc.2016.185

Gandy RC; Barbour AP; Samra J; Nikfarjam M; Haghighi K; Kench JG; Saxena P; Goldstein D, 2016, 'Refining the care of patients with pancreatic cancer: The AGITG Pancreatic Cancer Workshop consensus', Medical Journal of Australia, 204, pp. 419 - 422.e1, http://dx.doi.org/10.5694/mja16.00061

Gandy RC; Barbour AP; Samra J; Nikfarjam M; Haghighi K; Kench JG; Saxena P; Goldstein D, 2016, 'Refining the care of patients with pancreatic cancer: the AGITG Pancreatic Cancer Workshop consensus', MEDICAL JOURNAL OF AUSTRALIA, 204, pp. 419 - +, http://dx.doi.org/10.5694/mja16.00061

Scheithauer W; Ramanathan RK; Moore M; Macarulla T; Goldstein D; Hammel P; Kunzmann V; Liu H; McGovern D; Romano A; Von Hoff DD, 2016, 'Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: Phase III MPACT trial', Journal of Gastrointestinal Oncology, 7, pp. 469 - 478, http://dx.doi.org/10.21037/jgo.2016.01.03

Shaw JM; Shepherd HL; Durcinoska I; Butow PN; Liauw W; Goldstein D; Young JM, 2016, 'It’s all good on the surface: care coordination experiences of migrant cancer patients in Australia', Supportive Care in Cancer, 24, pp. 2403 - 2410, http://dx.doi.org/10.1007/s00520-015-3043-8

Burmeister EA; Jordan SJ; O’Connell DL; Beesley VL; Goldstein D; Gooden HM; Janda M; Merrett ND; Wyld D; Neale RE; Cosman PH; Bullen A; Burge M; Eastgate M; Powell J; Deuble M; Pryor D; Whelan J; Algie L; Gupta S; Lynch SV; Burmeister BH; Slater K; Fletcher D; Van Hazel G; Raftopoulos S; Spry N; Agar M; Brecciaroli F; Caird S; Cameron D; Chan P; Chantrill L; Christie D; Chua YJ; Croese J; Cronk M; Gani J; Grimison P; Hruby G; Jefford M; Samra JS; Wysocki AP, 2016, 'Using a Delphi process to determine optimal care for patients with pancreatic cancer', Asia-Pacific Journal of Clinical Oncology, 12, pp. 105 - 114, http://dx.doi.org/10.1111/ajco.12450

Barbour A; O'Rourke N; Chan H; Chua YJ; Kench J; Hicks RJ; Samra JS; Pavlakis N; Haghighi KS; Yip S; Donoghoe M; Friend C; Burge ME; Fawcett J; Harris M; Aghmesheh M; Joubert WL; Gebski V; Simes J; Goldstein D, 2016, 'Initial survival outcomes for the AGITG GAP study - a phase II study of perioperative nab-paclitaxel and gemcitabine for resectable pancreatic ductal adenocarcinoma (PDAC)', JOURNAL OF CLINICAL ONCOLOGY, 34, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.4105

Hammel P; Huguet F; Van Laethem JL; Goldstein D; Glimelius B; Artru P; Borbath I; Bouché O; Shannon J; André T; Mineur L; Chibaudel B; Bonnetain F; Louvet C, 2016, 'Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib the LAP07 randomized clinical trial', JAMA - Journal of the American Medical Association, 315, pp. 1844 - 1853, http://dx.doi.org/10.1001/jama.2016.4324

He EY; Hawkins NJ; Mak G; Roncolato F; Goldstein D; Liauw W; Clingan P; Chin M; Ward RL, 2016, 'The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study', ONCOLOGIST, 21, pp. 618 - 625, http://dx.doi.org/10.1634/theoncologist.2015-0530

Chiorean EG; Von Hoff DD; Reni M; Arena FP; Infante JR; Bathini VG; Wood TE; Mainwaring PN; Muldoon RT; Clingan PR; Kunzmann V; Ramanathan RK; Tabernero J; Goldstein D; McGovern D; Lu B; Ko A, 2016, 'CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer', Annals of Oncology, 27, pp. 654 - 660, http://dx.doi.org/10.1093/annonc/mdw006

Ramanathan RK; Goldstein D; Korn RL; Arena F; Moore M; Siena S; Teixeira L; Tabernero J; Van Laethem JL; Liu H; McGovern D; Lu B; Von Hoff DD, 2016, 'Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas', Annals of Oncology, 27, pp. 648 - 653, http://dx.doi.org/10.1093/annonc/mdw020

He EYJ; Hawkins NJ; Mak G; Roncolato F; Goldstein D; Liauw W; Clingan P; Chin M; Ward RL, 2016, 'The impact of mismatch repair status in colorectal cancer on the decision to treat with adjuvant chemotherapy: An Australian population-based multicenter study', Oncologist, 21, pp. 618 - 625, http://dx.doi.org/10.1634/theoncologist.2015-0530

Chantrill L; Goldstein D, 2016, 'Pancreatic cancer', Cancer Forum, 40, pp. 3 - 5

McLachlan SA; Fisher RJ; Zalcberg J; Solomon M; Burmeister B; Goldstein D; Leong T; Ackland SP; McKendrick J; McClure B; MacKay J; Ngan SY, 2016, 'The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04)', European Journal of Cancer, 55, pp. 15 - 26, http://dx.doi.org/10.1016/j.ejca.2015.10.060

Wang X; Goldstein D; Crowe P; Yang M; Garrett K; Zeps N; Yang JL, 2016, 'Overcoming resistance of targeted egfr monotherapy by inhibition of stat3 escape pathway in soft tisue sarcoma', Oncotarget, 7, pp. 21496 - 21509, http://dx.doi.org/10.18632/oncotarget.7452

Pothula SP; Xu Z; Goldstein D; Biankin AV; Pirola RC; Wilson JS; Apte MV, 2016, 'Hepatocyte growth factor inhibition: A novel therapeutic approach in pancreatic cancer', British Journal of Cancer, 114, pp. 269 - 280, http://dx.doi.org/10.1038/bjc.2015.478

Goldstein D; Chiorean EG; Tabernero J; El-Maraghi RH; Ma WW; Reni M; Harris M; Whorf RC; Coughlin S; Li J; Manax VG; Lu BD; Romano A; Von Hoff DD, 2016, 'Outcome of second-line treatment (2L Tx) following nab-paclitaxel (nab-P) + gemcitabine (G) or G alone for metastatic pancreatic cancer (MPC).', Journal of Clinical Oncology, 34, pp. 333 - 333, http://dx.doi.org/10.1200/jco.2016.34.4_suppl.333

Reichardt P; Demetri GD; Gelderblom H; Rutkowski P; Im SA; Gupta S; Kang YK; Schöffski P; Schuette J; Soulières D; Blay JY; Goldstein D; Fly K; Huang X; Corsaro M; Lechuga MJ; Martini JF; Heinrich MC, 2016, 'Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial', BMC Cancer, 16, pp. 22, http://dx.doi.org/10.1186/s12885-016-2051-5

O’Callaghan C; Schofield P; Butow P; Nolte L; Price M; Tsintziras S; Sze M; Thein T; Yiu D; Mireskandari S; Goldstein D; Jefford M, 2016, '“I might not have cancer if you didn’t mention it”: a qualitative study on information needed by culturally diverse cancer survivors', Supportive Care in Cancer, 24, pp. 409 - 418, http://dx.doi.org/10.1007/s00520-015-2811-9

Sharbeen G; McCarroll J; Liu J; Youkhana J; Limbri LF; Biankin AV; Johns A; Kavallaris M; Goldstein D; Phillips PA, 2016, 'Delineating the Role of βIV-Tubulins in Pancreatic Cancer: βIVb-Tubulin Inhibition Sensitizes Pancreatic Cancer Cells to Vinca Alkaloids', Neoplasia (United States), 18, pp. 753 - 764, http://dx.doi.org/10.1016/j.neo.2016.10.011

Goldstein D; Von Hoff DD; Moore M; Greeno E; Tortora G; Ramanathan RK; Macarulla T; Liu H; Pilot R; Ferrara S; Lu B, 2016, 'Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT)', European Journal of Cancer, 52, pp. 85 - 91, http://dx.doi.org/10.1016/j.ejca.2015.10.017

Goldstein D; Rosenberg JE; Figlin RA; Townsend RR; McCann L; Carpenter C; Pandite L, 2016, 'Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?', European Journal of Cancer, 53, pp. 96 - 104, http://dx.doi.org/10.1016/j.ejca.2015.10.006

Pothula SP; Xu Z; Goldstein D; Pirola RC; Wilson JS; Apte MV, 2016, 'Key role of pancreatic stellate cells in pancreatic cancer', Cancer Letters, http://dx.doi.org/10.1016/j.canlet.2015.10.035

Bridgewater J; Lopes A; Wasan H; Malka D; Jensen L; Okusaka T; Knox J; Wagner D; Cunningham D; Shannon J; Goldstein D; Moehler M; Bekaii-Saab T; McNamara MG; Valle JW, 2016, 'Prognostic factors for progression-free and overall survival in advanced biliary tract cancer', Annals of Oncology, 27, pp. 134 - 140, http://dx.doi.org/10.1093/annonc/mdv483

McCarroll JA; Teo J; Boyer C; Youkhana J; Sagnella S; Duong H; Sharbeen G; Goldstein D; Davis T; Kavallaris M; Phillips P; Liu J, 2016, 'A rationally optimized nanoparticle system for the delivery of RNA interference therapeutics into pancreatic tumors in vivo.', Biomacromolecules, 17, pp. 2337 - 2351, http://dx.doi.org/10.1021/acs.biomac.6b00185

Beesley VL; Janda M; Goldstein D; Gooden H; Merrett ND; O'Connell DL; Rowlands IJ; Wyld D; Neale RE, 2016, 'A tsunami of unmet needs: Pancreatic and ampullary cancer patients' supportive care needs and use of community and allied health services', Psycho-Oncology, 25, pp. 150 - 157, http://dx.doi.org/10.1002/pon.3887

Sharbeen G; Youkhana J; McCarroll J; Akerman A; Goldstein D; Phillips P, 2016, 'MutY-Homolog modulates pancreatic cancer cell survival and chemoresistance', Pancreatology, 16, pp. S5 - S5, http://dx.doi.org/10.1016/j.pan.2016.05.024

Oar AJ; Wong W; Chen C; Haghighi KS; Thompson S; Goldstein D, 2016, 'Stereotactic body hypofractionated radiotherapy for inoperable pancreatic cancer, with or without metastases', HPB, 18, pp. e359 - e359, http://dx.doi.org/10.1016/j.hpb.2016.02.932

Casali PG; Le Cesne A; Velasco AP; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom H; Adenis A; Hartmann JT; Duffaud F; Goldstein D; Broto JM; Gronchi A; Dei Tos AP; Marréaud S; Van Der Graaf WTA; Zalcberg JR; Litière S; Blay JY, 2015, 'Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in collaboration with the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas', Journal of Clinical Oncology, 33, pp. 4276 - 4283, http://dx.doi.org/10.1200/JCO.2015.62.4304

Donskov F; Michaelson MD; Puzanov I; Davis MP; Bjarnason GA; Motzer RJ; Goldstein D; Lin X; Cohen DP; Wiltshire R; Rini BI, 2015, 'Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients', British Journal of Cancer, 113, pp. 1571 - 1580, http://dx.doi.org/10.1038/bjc.2015.368

Chandrasegaram MD; Goldstein D; Simes J; Gebski V; Kench JG; Gill AJ; Samra JS; Merrett ND; Richardson AJ; Barbour AP; Fawcett J; Grimison PS; Christophi C; Padbury R; Haghighi KS; Chen JW; Nikfarjam M; O'Rourke N; Spry N, 2015, 'Meta-analysis of radical resection rates and margin assessment in pancreatic cancer', British Journal of Surgery, 102, pp. 1459 - 1472, http://dx.doi.org/10.1002/bjs.9892

Goldstein D; Fawcett J; Bridgewater J; Choti M; Wilson K; Gebski V; Aiken C; Eminton Z; Falk S; Stanton L; Primrose J, 2015, 'Feasibility of trials to assess safety and toxicity of peri-operative and post-operative adjuvant therapy for hepatic metastases from colorectal cancer', EUROPEAN JOURNAL OF CANCER, 51, pp. S343 - S343, http://dx.doi.org/10.1016/S0959-8049(16)30967-4

Stein A; Arnold D; Bridgewater J; Goldstein D; Jensen LH; Klümpen HJ; Lohse AW; Nashan B; Primrose J; Schrum S; Shannon J; Vettorazzi E; Wege H, 2015, 'Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial', BMC Cancer, 15, pp. 564, http://dx.doi.org/10.1186/s12885-015-1498-0

Jaeger U; Trneny M; Melzer H; Praxmarer M; Nawarawong W; Yehuda DB; Goldstein D; Mihaljevic B; Ilhan O; Ballova V; Hedenus M; Hsiao LT; Au WY; Burgstaller S; Weidinger G; Keil F; Dittrich C; Skrabs C; Klingler A; Chott A; Fridrik MA; Greil R, 2015, 'Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: Results of the randomized NHL13 trial', Haematologica, 100, pp. 955 - 963, http://dx.doi.org/10.3324/haematol.2015.125344

Apte MV; Xu Z; Pothula S; Goldstein D; Pirola RC; Wilson JS, 2015, 'Pancreatic cancer: The microenvironment needs attention too!', Pancreatology, 15, pp. S32 - S38, http://dx.doi.org/10.1016/j.pan.2015.02.013

Back to profile page